C6-and C9-substituted chromeno[4,3-c]isoxazoline derivatives...

Details C6-and C9-substituted chromeno[4,3-c]isoxazoline derivatives... C6-and C9-substituted chromeno[4,3-c]isoxazoline derivatives...

2003-08-19

2008-12-09

Saeed, Kamal (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C544S099000, C544S137000, C544S361000, C514S217100, C514S229500, C514S232500, C514S253030, C514S254040, C514S293000, C514S321000, C540S599000, C540S603000, C546S083000, C546S198000

Reexamination Certificate

active

07462717

ABSTRACT:
The invention concerns substituted tricyclic isoxazoline derivatives, more in particular tricyclic dihydrobenzopyranoisoxazoline, dihydroquinolinoisoxazoline, dihydronaphthalenoisoxazoline and dihydrobenzothiopyranoisoxazoline derivatives substituted on at least one of the C6- and C9-positions of the phenylpart of the tricyclic moiety with a selected radical, according to Formula (I)wherein X=CH2, N—R7, S or O, R1, R2, R14and R15are certain specific substituents, with the proviso that at least one of R14and R15is not hydrogen, Pir is preferably an optionally substituted piperidinyl or piperazinyl radical and R3represents an optionally substituted aromatic homocyclic or heterocyclic ring system including a partially or completely hydrogenated hydrocarbon chain of maximum 6 atoms long with which the ring system is attached to the Pir radical and which may contain one or more heteroatoms selected from the group of O, N and S; a process for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for the treatment of depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders. The compounds according to the invention have surprisingly been shown to have a serotonine (5-HT) reuptake inhibitor activity in combination with additional α2-adrenoceptor antagonist activity and show a strong anti-depressant activity without being sedative. The invention also relates to novel combination of isoxazoline derivatives according to the invention with one or more other compounds selected from the group of antidepressants, anxiolytics, anti-psychotics and anti-Parkinson's disease drugs to improve efficacy and/or onset of action.

REFERENCES:
patent: 7169786 (2007-01-01), Andres-Gil et al.
patent: 7265103 (2007-09-01), Andres-Gil et al.
patent: WO 95/07262 (1995-03-01), None
patent: WO 97/25317 (1997-07-01), None
patent: WO 02/066484 (2002-08-01), None
International Search Report for PCT/EP03/09532 dated Jan. 23, 2004.

Affiliated with

Also associated with

Rating

C6-and C9-substituted chromeno[4,3-c]isoxazoline derivatives... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with C6-and C9-substituted chromeno[4,3-c]isoxazoline derivatives..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C6-and C9-substituted chromeno[4,3-c]isoxazoline derivatives... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4046862